About: Effectiveness of Intravenous Immunoglobulin for Children with Severe COVID-19: A Rapid Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effectiveness of Intravenous Immunoglobulin for Children with Severe COVID-19: A Rapid Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effectiveness of Intravenous Immunoglobulin for Children with Severe COVID-19: A Rapid Review
Creator	Zhang, Jingyi Fu, Zhou Liu, Enmei Luo, Zhengxiu Huang, Liping Wang, Xia Zhou, Qi Chen, Yaolong Li, Weiguo Yang, Nan Lee, Myeong Ahn, Hyeong Fukuoka, Toshio Luo, Xufei Ma, Yanfang Yang, Kehu Yang, Yinmei
topic	covid:e3a80e7de600756dc0273af41fa0b10bf41232f9#this
Source	MedRxiv
abstract	Background: Intravenous immunoglobulin (IVIG) is usually used as supportive therapy, but the treatment of COVID-19 by IVIG is controversial. This rapid review aims to explore the clinical effectiveness and safety of IVIG in the treatment of children with severe COVID-19. Methods: We systematically searched the literature on the use of IVIG in patients with COVID-19, Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS), including both adults and children. We assessed the risk of bias and quality of evidence and reported the main findings descriptively. Results: A total of 1519 articles were identified by initial literature search, and finally six studies, included one randomized controlled trial (RCT), four case series and one case report involving 198 patients. One case series showed the survival of COVID-19 patients with acute respiratory distress syndrome (ARDS) was not improved by IVIG. One case report showed high-dose IVIG could improve the outcome of COVID-19 adults. Three observational studies showed inconsistent results of the effect of IVIG on SARS patients. One RCT showed that IVIG did not reduce mortality or the incidence of nosocomial infection in adults with severe SARS. The quality of evidence was between low and very low. Conclusions: The existing evidence is insufficient to support the efficacy or safety of IVIG in the treatment of COVID-19. Keywords: COVID-19; children; intravenous immunoglobulin; rapid review.
has issue date	2020-04-22(xsd:dateTime)
bibo:doi	10.1101/2020.04.17.20064444
has license	medrxiv
sha1sum (hex)	e3a80e7de600756dc0273af41fa0b10bf41232f9
schema:url	https://doi.org/10.1101/2020.04.17.20064444
resource representing a document's title	Effectiveness of Intravenous Immunoglobulin for Children with Severe COVID-19: A Rapid Review
resource representing a document's body	covid:e3a80e7de600756dc0273af41fa0b10bf41232f9#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/e3a80e7de600756dc0273af41fa0b10bf41232f9
is schema:about of	named entity 'Intravenous immunoglobulin' named entity 'Severe Acute Respiratory Syndrome (SARS)' named entity 'COVID-19' named entity 'systematically' named entity 'Effectiveness' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'SAFETY' named entity 'USE OF' named entity 'EFFECTIVENESS' named entity 'COVID-19' covid:arg/e3a80e7de600756dc0273af41fa0b10bf41232f9 named entity 'IVIG' named entity 'adults' named entity 'Title' named entity 'COVID-19' named entity 'supportive therapy' named entity 'IVIG' named entity 'Middle East Respiratory Syndrome' named entity 'Intravenous' named entity 'preprint' named entity 'public health' named entity 'preprint' named entity 'Wuhan seafood market' named entity 'epidemic' named entity 'IVIG' named entity 'preprint' named entity 'sensitivity analysis' named entity 'hormone' named entity 'infection' named entity 'lung' named entity 'preprint' named entity 'Wuhan seafood market' named entity 'University of Geneva' named entity 'IVIG' named entity 'IVIG' named entity 'Gammagard' named entity 'infection' named entity 'kidney failure' named entity 'antiviral therapy' named entity 'Wuhan Coronavirus' named entity '2019-nCoV' named entity 'SARS' named entity 'peer review' named entity 'AHRQ' named entity 'glucocorticoids' named entity 'IVIG' named entity 'thrombosis' named entity 'enveloped viruses' named entity 'COVID-19' named entity 'COVID-19' named entity 'renal failure' named entity 'IVIG' named entity 'preprint' named entity 'medRxiv' named entity 'risk of death' named entity 'biochemical' named entity 'WBC' named entity 'Severe Acute Respiratory Syndrome' named entity 'ARDS' named entity 'medRxiv' named entity 'IVIG' named entity 'allocation concealment' named entity 'IVIG' named entity 'antiviral treatment' named entity 'gamma-globulin' named entity 'medRxiv' named entity 'SARS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software